Lupin Ltd: Emerging Strong - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Lupin Ltd: Emerging Strong

Dec 18, 2001

Last year, Lupin Chemicals and Lupin Laboratories merged to create a giant entity, Lupin Ltd., with sales turnover in excess of Rs 9 bn. The merger has helped the company in consolidating its leadership position in the anti –TB market. Further, the company is taking strides to become a recognized global player in the Cephalosporin (new generation anti-infectives) and is now considering research as a new thrust area. Lupin Chemicals manufactured Rifampicin while Lupin Laboratories manufactured Ethambutol. Together both these molecules command almost the entire anti-TB market. The consolidation helped the company in becoming a world leader in the anti-TB market, with a market share of more than 40% in the domestic anti-TB market, which is estimated at Rs 3.3 bn. In a segment, which registered, de-growth in last two years, Lupin recorded a double-digit growth in this segment.

A higher incidence of HIV in the developed nations has resulted in significant rise in TB cases worldwide. Further, with global agencies like WHO funding anti-TB drugs, the global market is expected to grow considerably after witnessing a plateau. Lupin plans to enter into US$550 m global anti-TB market and is creating a manufacturing facility at Aurangabad with a capital outlay of Rs 200 m, complying with the US FDA specifications. Lupin aims to achieve more than 50% global market share in the anti-TB segment.

The new thrust area for the company is Cephalosporins. Lupin has just commenced a state of art US FDA approved oral Cephalosporin bulk active plant. Cephalosporin enjoys global sales of US $ 11 bn. Several combinations of Cephalosporins, injectable and orals are going off patent. This provides the company good opportunity to develop competencies and launch these products in the generics market.

Lupin plans to market its Cefotaxime Sodium in the US through its US partner, American Pharmaceutical Partners (APP). Cefotaxime formulations have reported sales of US$ 100 m in the year 2000. Lupin will supply the bulk drug to APP who in turn will formulate and market the product in the US. The company expects to achieve sales of US$ 14 m (Rs 680 m) in the first year of launch. The company has identified four other anti-infective molecules whose patents expire in 2002.

The company is also aggressively launching new products to reduce its therapeutic segment dependence. The company has launched new products in cardiovascular, cephalosporin and herbal segments with plans to launch 40 new products in the current year. Lupin also plans to become a dominant player in the phytochemistry (alternative medicine) segment and has launched a range of products. The company has recently launched 3 herbal products namely: Anxicalm for anxiety, J.Wort for depression and Fibril Rich for the regulation of bowel movement.

Though late, Lupin is now recognizing R&D as a thrust area. The company has established state-of-the-art R&D centre spread over an area of 19 acres at Pune. Lupin has 6 molecules in the pipeline and has plans to file 4 ANDA and 2 INDA in FY02 in the area of neurology, asthma, dermatology, herbal medicines and NDDS (New Drug Delivery System) in Cephalosporins.

The merger has helped Lupin to catapult its position in the league of few Indian pharma companies with Rs 10 bn plus mark. However, company lacks presence in specialty pharma segment and both the company’s key segments (anti-TB and Cephalosporin) are highly price competitive and margins are unlikely to be lucrative. Hence, Lupin would have to push hard to drive growth in the domestic market. In the exports front, though the company is taking the right steps, it seems to be a bit late in cashing on the generic opportunity as it lacks an ANDA pipeline. Even on the exports front, the company would face competition from players from domestic pharma majors.

However, the company seems to be rushing to make up for being a late entrant. To summarize, though the road ahead would not be smooth and easy, the company seems to have right plans in place. At the current market price of Rs 115, the stock trades at 7.6x FY01 earnings.

Equitymaster requests your view! Post a comment on "Lupin Ltd: Emerging Strong". Click here!


More Views on News

LUPIN 2020-21 Annual Report Analysis (Annual Result Update)

Oct 19, 2021 | Updated on Oct 19, 2021

Here's an analysis of the annual report of LUPIN for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

Lupin Gains 16% in a Month. Here's Why it Could Rally More (Views On News)

Jun 4, 2021

Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 6, 2021 03:36 PM